Latest News

Date Title Topic
06 Feb 2017 EMA Recommends Granting a Marketing Authorisation for Hybrid Methotrexate Haematologic malignancies - Anticancer agents & Biologic therapy
03 Feb 2017 FDA Grants Accelerated Approval to Nivolumab for Treatment of Advanced Urothelial Carcinoma Genitourinary cancers - Cancer Immunology and Immunotherapy
02 Feb 2017 ESMO advocates for Cancer Resolution at WHO Executive Board Meeting
02 Feb 2017 Council of Europe Data Protection Day Guidelines to Protect the People Behind Big Data Bioethics, legal and economic issues
01 Feb 2017 Nature Reviews Clinical Oncology – Year in Review Genitourinary cancers - Haematologic malignancies - Endocrine and neuroendocrine tumours - Sarcomas - Lung and other thoracic tumours - Head and neck cancers
31 Jan 2017 Withdrawal of the Application for a Change to the Marketing Authorisation for Denosumab Palliative and supportive care
30 Jan 2017 EMA Recommends Extension of Indications for Lenalidomide in Multiple Myeloma Haematologic malignancies - Anticancer agents & Biologic therapy
27 Jan 2017 NICE Issues Technology Appraisal Guidance for Ibrutinib for Previously Treated CLL and Untreated CLL with 17p Deletion or TP53 Mutation Haematologic malignancies - Anticancer agents & Biologic therapy
Seventh European Advocacy in Action Forum 2016
26 Jan 2017 Nivolumab as Salvage Therapy in Pretreated Patients with Advanced Gastric or Gastro-oesophageal Junction Cancer Gastrointestinal cancers - Cancer Immunology and Immunotherapy
25 Jan 2017 NICE Issues Recommendations for Pomalidomide in Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib Haematologic malignancies - Anticancer agents & Biologic therapy
23 Jan 2017 Palliative Care Fellowships
23 Jan 2017 Ibrutinib, First FDA-Approved Therapy for Marginal Zone Lymphoma Haematologic malignancies - Anticancer agents & Biologic therapy
20 Jan 2017 GI Cancer Patient Guides Now in Portuguese: Colorectal, Liver, Oesophageal, Pancreatic and Stomach Cancer
Application